CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alkermes, Inc. (NASDAQ: ALKS) today announced that it initiated an accelerated share repurchase (ASR) program under which the company will repurchase $60 million of its common stock. The repurchase will be funded with the company’s existing cash, which includes proceeds from the recent sale of its stake in Reliant Pharmaceuticals, Inc.
